title: Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport.
abstract: The effect of a synthetic somatostatin analog was studied in a patient with severe secretory diarrhea due to pancreatic cholera syndrome. Basal intestinal perfusion studies indicated an absence of water and sodium absorption, and active chloride secretion in the small bowel. Intravenous administration of the somatostatin analog (1 microgram/kg.h) changed zero net water movement to absorption (122 mL/30 cm of the jejunum per hour). Chloride secretion changed to absorption (5.0 to 7.9 meq/30 cm.h), and plasma vasoactive intestinal polypeptide concentration was reduced from 330 to 45 pmol/L (normal, less than 51). When the analog was given subcutaneously, 100 micrograms twice daily, stool weight decreased, and plasma vasoactive intestinal polypeptide concentration fell toward the normal range (67 pmol/L). Plasma concentration of pancreatic polypeptide was initially elevated and dropped during intravenous infusion of somatostatin analog but returned to baseline on maintenance therapy with the analog delivered subcutaneously. The patient has not had further diarrhea during 9 months of therapy.
authors.forename: W C
authors.initials: WC
authors.lastname: Santangelo
authors.forename: T M
authors.initials: TM
authors.lastname: O'Dorisio
authors.forename: J G
authors.initials: JG
authors.lastname: Kim
authors.forename: G
authors.initials: G
authors.lastname: Severino
authors.forename: G J
authors.initials: GJ
authors.lastname: Krejs
mesh_terms: D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D000368:Aged; D005243:Feces / Q000187:drug effects; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007408:Intestinal Absorption / Q000187:drug effects*; D007583:Jejunum; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010191:Pancreatic Polypeptide / Q000097:blood; D010477:Perfusion; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D014660:Vasoactive Intestinal Peptide / Q000097:blood; D003969:Vipoma / Q000188:drug therapy* / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000187:drug effects*
chemical_list: D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D015282:Octreotide